Skip to main content

Bundle read#1: genomic correlation with immunotherapy's effectiveness

Continuing the huge trend of discovering more into the magical "immune checkpoint blockade" therapy (as the hottest field that shed hope to cancer treatment), more is to be discussed about them. As is designed to battle against body's own mechanisms that suppress immune cells, those drugs as Ipilimumab and Nivolumab potentiate patients' own immune systems so that they are able to do their jobs and to control tumor growth. Despite the exciting efficacy of these drugs in melanoma, one of the puzzles is the different reponsiveness among patients.

Two papers just came out about the topic. While Ipilimumab (CTLA-4 inhibitor) and Nivolumab (PD-1 inhibitor) were individually discussed in each paper, similar correlation of the responsiveness of immune checkpoint blockade therapy with genomic alteration in melanoma patients were found.

High mutation loads tend to correlate with a favorable clinical response of both Ipilimumab and Nivolumab. However as suggested in the Science paper (other also other papers), further characterization of neoantigens produced by the genetic alterations will probably be more meaningful to predictive clinical outcomes. Recurrent neoantigens were also observed in response group of melanoma patients, suggesting that these neoantigens could be tested to decide whether Ipilimumab should be used in the patient. On the other hand, mutation loads were able to predict survival rate but not response rate of melanoma patients treated with Nivolumab, possibly also suggesting the needs for further characterization.

Besides, characterization of gene expression provided interesting information about Nivolumab response. The non-responders seemed to express higher genes related to angiogenesis, vasculature development and epithelial-mesenchymal transition (EMT) processed, which could help tumor cells escape from immune surveillance. Moreover, MAPKi therapy, widely used in multiple cancer treatment, also seemed to be associated with the "non-responding" phenotype, suggesting that the treatment plan that a patient is receiving could cause him/her insensitive to immune therapy. Of course, most that we learn from these studies are "correlation" not "causal"- we get a lot of information but we still need more to understand "the whole story".

Comments

Popular posts from this blog

The "UV tanning pathway" and melanoma

As it is summertime now, I must not be the only one who can’t wait to jump into the pool and give myself a tan. Bronzy cheeks and bodies are currently the big trend in the fashion industry. It also seems to be everyone of my friends’ dream and ultimate goal. However, have you noticed the fact that some people can easily get tan s wh en some only get sunburn s ? If you happen to belong to the latter group, stop trying so hard to bathe in more sun, because you are also at higher risk of getting melanoma. Melanoma is a type of skin cancer that develops from melanocytes - the cells that produce pigment in the skin . Melanoma only contributes a small proportion of all skin cancer s but counts for the large majority of skin cancer deaths. In fact, it is highly associated with ultraviolet (UV) radiation, of which most exposure is due to direct sunlight and tanning beds. So before you get ready to dive into the sun, here is something you should know about the science behind the t...

Farewell to the cell biology giant: in memory of Alan Hall

I was so shocked to hear the sudden death of Dr. Alan Hall, the chair of Cell Biology Program of Memorial Sloan Kettering Cancer Center (MSKCC) and a truly great scientist. It was such an unexpected heart attack that left everyone in a great sorrow this week. Alan is such a fantastic scientist that has made tremendous contribution to the field of cell biology, cytoskeleton( bone structure of a cell) in particular. He is also a kind and inspiring mentor in our mind... The institute had a rather short memorial this Thursday and we will be having a more formal one later when his family get back from UK (his hometown).  Even to people outside the cytoskeleton field, the contribution that Dr. Hall has made is so important that it provides basis of many of the discoveries that were made in the past 20 years. The cytoskeleton, as the supporting structure of cells, functions to maintain the shape and motion of cells. As such dynamic structure, the mechanisms of it has always been i...

Normal skin carry ONCOGENIC MUTATIONS- from the standpoint of cancer evolution

We have been long conceived that cancer cells are formed from developing oncogenic mutations during proliferation. On the other hand, it is very natural to think that normal tissue cells should have no or maybe very few (just to make it not too absolute) mutations. However, the latest Science paper by Martincorena et al . suggests that normal skin tissues do carry oncogenic mutations, in an amount that may be higher than you thought. The group of scientists collected 234 biopsies of normal eyelid skin tissues from 4 individuals and sequenced 74 known cancer genes in them. What they've found is that the mutation rate of these genes in the sequenced skin tissues is actually as high as in many type of cancer tissues! It is comparable to the mutation rates of breast cancer and is only a factor of 10 less than that in a type of skin carcinoma! How do healthy people, including us, have so many mutations in normal skin tissues? The answer is: sunlight. The study looked into specific ...